Enreca Health > About Enreca Health > Participants > CMP
Centre for Medical Parasitology (CMP)
Institutional background
The Centre for Medical Parasitology and International Health (CMP) is formed by research groups based at the University of Copenhagen and at the Copenhagen University Hospital (Rigshospitalet): The Centre include researchers from Institute for Medical Microbiology and Immunology and Institute of Public Health (University of Copenhagen), and the Departments of Infectious Diseases and Clinical Microbiology (Copenhagen University Hospital).
Research focus
CMP’s main focal area is malaria and its impact on public health in low-income countries, particularly in Africa. Other focal areas include leishmaniasis and filariasis. Research is centred on vaccine development, malaria in pregnancy, drug resistance development, clinical pharmacology/ drug therapy in vulnerable groups, including children and pregnant women, and on health systems research related to malaria.
Researcher profiles
CMP is comprised of staff with capacity within medicine, epidemiology/immunology, parasitology, molecular biology, and international public health. The staff of CMP has research experience from Ghana, Tanzania, Sudan and India. Approximately 50 researchers and technicians are affiliated to CMP.
Research collaboration
CMP is part of a well-established international scientific network, composed of scientist in Europe, Africa, America and Australia.
|
The Centre participates in the European Malaria Vaccine Consortium |
|
|
Gates Malaria Partnership |
|
|
Joint Malaria Programme |
|
|
CMP is involved in the new European Programme for Malaria, HIV and Tuberculosis called ‘European and Developing Countries Clinical Trials Partnership’ (EDCTP) |
CMP also takes part in a central initiative to bid for an Integrated Project on Malaria Vaccine Development under the 6th EU framework programme.
Capacity development
CMP’s research programmes include comprehensive and sustained capacity building in collaboration with research institutions in low income countries. Since 2000, 28 PhD’s have graduated through affiliation to CMP.
Consultancies
Representatives of CMP are acting as advisors to WHO and the Global Fund on malaria treatment policies and guidelines.
Peer reviewed publications
Alilio M, Kitua A, Njunwa K, Medina M, Rønn AM, Mhina J, Msuya F, Mahundi J, Depinay JM, Whyte S, Krasnik A and Bygbjerg IC. Malaria control at the district level in Africa: a case of Muheza district, North-eastern Tanzania. J Am Soc Trop Med Hyg (in press).
Staalsoe T, Shulman CE, Dorman EK, Kawuondo K, Marsh K and Hviid L. Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae (IPTp) reduces plasma levels of IgG protecting against pregnancy-associated Plasmodium falciparum malaria. Infect Immun 72 (in press)
Jensen ATR, Magistrado P, Sharp S, Joergensen L, Lavstsen T, Chiucchiuini A, Salanti A, Vestergaard LS, Lusingu JP, Hermsen R, Sauerwein R, Christensen J, Nielsen MA, Hviid L, Sutherland C, Staalsoe T and Theander TG. Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by Group A var genes. J Exp Med 199: 1-13, 2004 [PubMed]
Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K and Hviid L. Variant surface antigen-specific IgG and protection against the clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 363: 283-289, 2004
Alifrangis M, Lemnge MM, Rønn AM, Segeja MD, Magesa SM, Khalil IF and Bygbjerg IC. Increasing prevalence of wildtypes in the dihydrofolate reductase gene of Plasmodium falciparum in an area with high levels of sulfadoxine/pyrimethamine resistance after introduction of treated bed nets. Am J Trop Med Hyg 69: 238-243, 2003 [PubMed]
Massaga JJ, Kitua AY, Lemnge MM, Akida JA, Malle LN, Rønn AM, Theander TG and Bygbjerg IC. Intermittent treatment with amodiaquine markedly reduces the incidence of anaemia and malaria fevers during the first year of life: a randomised placebo controlled trial in a district of Tanzania highly endemic for drug resistant malaria. Lancet 361: 1853-1860, 2003 [PubMed]
Alifrangis M, Enosse S, Khalil IF, Tarimo DS, Lemnge MM, Thompson R, Bygbjerg IC and Rønn AM. Prediction of Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in vivo by mutations in the dhfr and dhps genes - a comparative study between sites of differing endemicity. Am J Trop Med Hyg 69 601-606, 2003.
Salanti A, Staalsoe T, Lavstsen T, Jensen ATR, Sowa MPK, Arnot DE, Hviid L and Theander TG. Selective up-regulation of a single distinctly structured var gene in CSA-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol 49: 179-191, 2003 [PubMed]
Nielsen MA, Staalsoe T, Kurtzhals JAL, Goka BQ, Dodoo D, Alifrangis M, Theander TG, Akanmori BD and Hviid L. Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and non-severe malaria and is modified by acquired immunity. J Immunol 168: 3444-3450, 2002
Khalil IF, Alifrangis M, Rønn AM, Gabar HA, Jelinek T, Satti GMH and Bygbjerg IC. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome. Am J Trop Med Hyg 67: 225-229, 2002
